Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited TEVA Peers
See (TEVA) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TEVA | $17.96 | +6.08% | 20.58B | -15.62 | -$1.15 | N/A |
| ZTS | $161.96 | +1.69% | 72.11B | 29.08 | $5.57 | +1.15% |
| HLN | $10.72 | -0.23% | 48.33B | 25.51 | $0.42 | +1.57% |
| TAK | $14.20 | -1.15% | 44.75B | 31.54 | $0.45 | +4.15% |
| ITCI | $131.87 | N/A | 14.05B | -180.64 | -$0.73 | N/A |
| NBIX | $120.43 | +4.08% | 11.92B | 40.69 | $2.96 | N/A |
| RDY | $13.94 | +3.99% | 11.61B | 18.34 | $0.76 | +0.69% |
| CTLT | $63.48 | N/A | 11.52B | -27.84 | -$2.28 | N/A |
| VTRS | $8.96 | +2.17% | 10.52B | -16.91 | -$0.53 | +5.37% |
| ELAN | $12.82 | +7.19% | 6.37B | 17.09 | $0.75 | N/A |
Stock Comparison
TEVA vs ZTS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ZTS has a market cap of 72.11B. Regarding current trading prices, TEVA is priced at $17.96, while ZTS trades at $161.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ZTS's P/E ratio is 29.08. In terms of profitability, TEVA's ROE is -0.26%, compared to ZTS's ROE of +0.50%. Regarding short-term risk, TEVA is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs HLN Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, HLN has a market cap of 48.33B. Regarding current trading prices, TEVA is priced at $17.96, while HLN trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas HLN's P/E ratio is 25.51. In terms of profitability, TEVA's ROE is -0.26%, compared to HLN's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs TAK Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TAK has a market cap of 44.75B. Regarding current trading prices, TEVA is priced at $17.96, while TAK trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TAK's P/E ratio is 31.54. In terms of profitability, TEVA's ROE is -0.26%, compared to TAK's ROE of +0.04%. Regarding short-term risk, TEVA is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs ITCI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ITCI has a market cap of 14.05B. Regarding current trading prices, TEVA is priced at $17.96, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TEVA's ROE is -0.26%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, TEVA is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs NBIX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, NBIX has a market cap of 11.92B. Regarding current trading prices, TEVA is priced at $17.96, while NBIX trades at $120.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas NBIX's P/E ratio is 40.69. In terms of profitability, TEVA's ROE is -0.26%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, TEVA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs RDY Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, RDY has a market cap of 11.61B. Regarding current trading prices, TEVA is priced at $17.96, while RDY trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas RDY's P/E ratio is 18.34. In terms of profitability, TEVA's ROE is -0.26%, compared to RDY's ROE of +0.18%. Regarding short-term risk, TEVA is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs CTLT Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CTLT has a market cap of 11.52B. Regarding current trading prices, TEVA is priced at $17.96, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TEVA's ROE is -0.26%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, TEVA is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs VTRS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, VTRS has a market cap of 10.52B. Regarding current trading prices, TEVA is priced at $17.96, while VTRS trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas VTRS's P/E ratio is -16.91. In terms of profitability, TEVA's ROE is -0.26%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TEVA is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ELAN Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ELAN has a market cap of 6.37B. Regarding current trading prices, TEVA is priced at $17.96, while ELAN trades at $12.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ELAN's P/E ratio is 17.09. In terms of profitability, TEVA's ROE is -0.26%, compared to ELAN's ROE of +0.05%. Regarding short-term risk, TEVA is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs RGC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, RGC has a market cap of 6.08B. Regarding current trading prices, TEVA is priced at $17.96, while RGC trades at $467.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas RGC's P/E ratio is -1460.75. In terms of profitability, TEVA's ROE is -0.26%, compared to RGC's ROE of -0.25%. Regarding short-term risk, TEVA is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs LNTH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, LNTH has a market cap of 5.50B. Regarding current trading prices, TEVA is priced at $17.96, while LNTH trades at $79.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas LNTH's P/E ratio is 18.24. In terms of profitability, TEVA's ROE is -0.26%, compared to LNTH's ROE of +0.29%. Regarding short-term risk, TEVA is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs PRGO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PRGO has a market cap of 3.71B. Regarding current trading prices, TEVA is priced at $17.96, while PRGO trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PRGO's P/E ratio is -22.50. In terms of profitability, TEVA's ROE is -0.26%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, TEVA is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs AMRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AMRX has a market cap of 3.54B. Regarding current trading prices, TEVA is priced at $17.96, while AMRX trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AMRX's P/E ratio is -190.00. In terms of profitability, TEVA's ROE is -0.26%, compared to AMRX's ROE of -0.00%. Regarding short-term risk, TEVA is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ALVO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ALVO has a market cap of 3.09B. Regarding current trading prices, TEVA is priced at $17.96, while ALVO trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ALVO's P/E ratio is -11.78. In terms of profitability, TEVA's ROE is -0.26%, compared to ALVO's ROE of +0.46%. Regarding short-term risk, TEVA is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs EVO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EVO has a market cap of 2.96B. Regarding current trading prices, TEVA is priced at $17.96, while EVO trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EVO's P/E ratio is -6.32. In terms of profitability, TEVA's ROE is -0.26%, compared to EVO's ROE of -0.19%. Regarding short-term risk, TEVA is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ALVOW Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ALVOW has a market cap of 2.92B. Regarding current trading prices, TEVA is priced at $17.96, while ALVOW trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ALVOW's P/E ratio is N/A. In terms of profitability, TEVA's ROE is -0.26%, compared to ALVOW's ROE of +0.46%. Regarding short-term risk, TEVA is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs HCM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, HCM has a market cap of 2.51B. Regarding current trading prices, TEVA is priced at $17.96, while HCM trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas HCM's P/E ratio is 69.60. In terms of profitability, TEVA's ROE is -0.26%, compared to HCM's ROE of +0.05%. Regarding short-term risk, TEVA is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs DCPH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, DCPH has a market cap of 2.21B. Regarding current trading prices, TEVA is priced at $17.96, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TEVA's ROE is -0.26%, compared to DCPH's ROE of -0.52%. Regarding short-term risk, TEVA is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs EMBCV Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EMBCV has a market cap of 1.91B. Regarding current trading prices, TEVA is priced at $17.96, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TEVA's ROE is -0.26%, compared to EMBCV's ROE of -0.08%. Regarding short-term risk, TEVA is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SUPN Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SUPN has a market cap of 1.80B. Regarding current trading prices, TEVA is priced at $17.96, while SUPN trades at $32.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SUPN's P/E ratio is 24.36. In terms of profitability, TEVA's ROE is -0.26%, compared to SUPN's ROE of +0.08%. Regarding short-term risk, TEVA is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs BHC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BHC has a market cap of 1.76B. Regarding current trading prices, TEVA is priced at $17.96, while BHC trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BHC's P/E ratio is -39.75. In terms of profitability, TEVA's ROE is -0.26%, compared to BHC's ROE of +0.05%. Regarding short-term risk, TEVA is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs BGM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BGM has a market cap of 1.69B. Regarding current trading prices, TEVA is priced at $17.96, while BGM trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BGM's P/E ratio is -57.87. In terms of profitability, TEVA's ROE is -0.26%, compared to BGM's ROE of N/A. Regarding short-term risk, TEVA is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs TARO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TARO has a market cap of 1.62B. Regarding current trading prices, TEVA is priced at $17.96, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TARO's P/E ratio is 30.05. In terms of profitability, TEVA's ROE is -0.26%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TEVA is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs INDV Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, INDV has a market cap of 1.41B. Regarding current trading prices, TEVA is priced at $17.96, while INDV trades at $11.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas INDV's P/E ratio is -226.80. In terms of profitability, TEVA's ROE is -0.26%, compared to INDV's ROE of -0.01%. Regarding short-term risk, TEVA is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ANIP Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ANIP has a market cap of 1.34B. Regarding current trading prices, TEVA is priced at $17.96, while ANIP trades at $62.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ANIP's P/E ratio is -59.90. In terms of profitability, TEVA's ROE is -0.26%, compared to ANIP's ROE of -0.04%. Regarding short-term risk, TEVA is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs DVAX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, DVAX has a market cap of 1.18B. Regarding current trading prices, TEVA is priced at $17.96, while DVAX trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas DVAX's P/E ratio is -19.70. In terms of profitability, TEVA's ROE is -0.26%, compared to DVAX's ROE of +0.04%. Regarding short-term risk, TEVA is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs PCRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PCRX has a market cap of 1.16B. Regarding current trading prices, TEVA is priced at $17.96, while PCRX trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PCRX's P/E ratio is -11.67. In terms of profitability, TEVA's ROE is -0.26%, compared to PCRX's ROE of -0.12%. Regarding short-term risk, TEVA is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs AMPH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AMPH has a market cap of 1.15B. Regarding current trading prices, TEVA is priced at $17.96, while AMPH trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AMPH's P/E ratio is 7.95. In terms of profitability, TEVA's ROE is -0.26%, compared to AMPH's ROE of +0.22%. Regarding short-term risk, TEVA is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs PAHC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PAHC has a market cap of 992.34M. Regarding current trading prices, TEVA is priced at $17.96, while PAHC trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PAHC's P/E ratio is 51.04. In terms of profitability, TEVA's ROE is -0.26%, compared to PAHC's ROE of +0.07%. Regarding short-term risk, TEVA is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs HROW Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, HROW has a market cap of 978.41M. Regarding current trading prices, TEVA is priced at $17.96, while HROW trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas HROW's P/E ratio is -54.41. In terms of profitability, TEVA's ROE is -0.26%, compared to HROW's ROE of -0.28%. Regarding short-term risk, TEVA is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs COLL Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, COLL has a market cap of 950.12M. Regarding current trading prices, TEVA is priced at $17.96, while COLL trades at $29.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas COLL's P/E ratio is 15.89. In terms of profitability, TEVA's ROE is -0.26%, compared to COLL's ROE of +0.31%. Regarding short-term risk, TEVA is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs AVDL Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AVDL has a market cap of 926.70M. Regarding current trading prices, TEVA is priced at $17.96, while AVDL trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AVDL's P/E ratio is -18.80. In terms of profitability, TEVA's ROE is -0.26%, compared to AVDL's ROE of -0.66%. Regarding short-term risk, TEVA is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs PETQ Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PETQ has a market cap of 919.17M. Regarding current trading prices, TEVA is priced at $17.96, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TEVA's ROE is -0.26%, compared to PETQ's ROE of +0.06%. Regarding short-term risk, TEVA is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs CRON Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CRON has a market cap of 790.11M. Regarding current trading prices, TEVA is priced at $17.96, while CRON trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CRON's P/E ratio is 18.64. In terms of profitability, TEVA's ROE is -0.26%, compared to CRON's ROE of +0.04%. Regarding short-term risk, TEVA is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs EMBC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EMBC has a market cap of 721.45M. Regarding current trading prices, TEVA is priced at $17.96, while EMBC trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EMBC's P/E ratio is 12.54. In terms of profitability, TEVA's ROE is -0.26%, compared to EMBC's ROE of -0.08%. Regarding short-term risk, TEVA is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs EOLS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EOLS has a market cap of 643.47M. Regarding current trading prices, TEVA is priced at $17.96, while EOLS trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EOLS's P/E ratio is -12.32. In terms of profitability, TEVA's ROE is -0.26%, compared to EOLS's ROE of -4.10%. Regarding short-term risk, TEVA is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ZYBT Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ZYBT has a market cap of 636.23M. Regarding current trading prices, TEVA is priced at $17.96, while ZYBT trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ZYBT's P/E ratio is 223.75. In terms of profitability, TEVA's ROE is -0.26%, compared to ZYBT's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs BDSI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BDSI has a market cap of 577.05M. Regarding current trading prices, TEVA is priced at $17.96, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TEVA's ROE is -0.26%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TEVA is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs TLRY Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TLRY has a market cap of 463.52M. Regarding current trading prices, TEVA is priced at $17.96, while TLRY trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TLRY's P/E ratio is -0.42. In terms of profitability, TEVA's ROE is -0.26%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, TEVA is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs KMDA Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, KMDA has a market cap of 392.18M. Regarding current trading prices, TEVA is priced at $17.96, while KMDA trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas KMDA's P/E ratio is 27.28. In terms of profitability, TEVA's ROE is -0.26%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, TEVA is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs SIGA Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SIGA has a market cap of 390.58M. Regarding current trading prices, TEVA is priced at $17.96, while SIGA trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SIGA's P/E ratio is 4.56. In terms of profitability, TEVA's ROE is -0.26%, compared to SIGA's ROE of +0.33%. Regarding short-term risk, TEVA is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ORGO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ORGO has a market cap of 378.66M. Regarding current trading prices, TEVA is priced at $17.96, while ORGO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ORGO's P/E ratio is -298.50. In terms of profitability, TEVA's ROE is -0.26%, compared to ORGO's ROE of +0.00%. Regarding short-term risk, TEVA is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs TKNO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TKNO has a market cap of 377.29M. Regarding current trading prices, TEVA is priced at $17.96, while TKNO trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TKNO's P/E ratio is -12.39. In terms of profitability, TEVA's ROE is -0.26%, compared to TKNO's ROE of -0.32%. Regarding short-term risk, TEVA is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SNDL Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SNDL has a market cap of 339.64M. Regarding current trading prices, TEVA is priced at $17.96, while SNDL trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SNDL's P/E ratio is -4.40. In terms of profitability, TEVA's ROE is -0.26%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, TEVA is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs EBS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EBS has a market cap of 317.25M. Regarding current trading prices, TEVA is priced at $17.96, while EBS trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EBS's P/E ratio is -1.62. In terms of profitability, TEVA's ROE is -0.26%, compared to EBS's ROE of -0.37%. Regarding short-term risk, TEVA is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs ALIM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ALIM has a market cap of 301.29M. Regarding current trading prices, TEVA is priced at $17.96, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TEVA's ROE is -0.26%, compared to ALIM's ROE of -0.34%. Regarding short-term risk, TEVA is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs AQST Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AQST has a market cap of 283.06M. Regarding current trading prices, TEVA is priced at $17.96, while AQST trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AQST's P/E ratio is -5.59. In terms of profitability, TEVA's ROE is -0.26%, compared to AQST's ROE of +1.00%. Regarding short-term risk, TEVA is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ACB Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ACB has a market cap of 277.71M. Regarding current trading prices, TEVA is priced at $17.96, while ACB trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ACB's P/E ratio is 25.30. In terms of profitability, TEVA's ROE is -0.26%, compared to ACB's ROE of -0.06%. Regarding short-term risk, TEVA is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs CGC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CGC has a market cap of 264.39M. Regarding current trading prices, TEVA is priced at $17.96, while CGC trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CGC's P/E ratio is -0.40. In terms of profitability, TEVA's ROE is -0.26%, compared to CGC's ROE of -0.88%. Regarding short-term risk, TEVA is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs LNDC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, LNDC has a market cap of 263.63M. Regarding current trading prices, TEVA is priced at $17.96, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TEVA's ROE is -0.26%, compared to LNDC's ROE of -0.65%. Regarding short-term risk, TEVA is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs LFCR Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, LFCR has a market cap of 258.44M. Regarding current trading prices, TEVA is priced at $17.96, while LFCR trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas LFCR's P/E ratio is -4.75. In terms of profitability, TEVA's ROE is -0.26%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, TEVA is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs TYHT Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TYHT has a market cap of 229.17M. Regarding current trading prices, TEVA is priced at $17.96, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TEVA's ROE is -0.26%, compared to TYHT's ROE of -0.84%. Regarding short-term risk, TEVA is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs REPH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, REPH has a market cap of 177.42M. Regarding current trading prices, TEVA is priced at $17.96, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas REPH's P/E ratio is -8.04. In terms of profitability, TEVA's ROE is -0.26%, compared to REPH's ROE of -0.15%. Regarding short-term risk, TEVA is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs OGI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, OGI has a market cap of 161.61M. Regarding current trading prices, TEVA is priced at $17.96, while OGI trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas OGI's P/E ratio is -3.66. In terms of profitability, TEVA's ROE is -0.26%, compared to OGI's ROE of -0.18%. Regarding short-term risk, TEVA is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs ESPR Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ESPR has a market cap of 158.34M. Regarding current trading prices, TEVA is priced at $17.96, while ESPR trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ESPR's P/E ratio is -2.85. In terms of profitability, TEVA's ROE is -0.26%, compared to ESPR's ROE of +0.15%. Regarding short-term risk, TEVA is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs DERM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, DERM has a market cap of 157.92M. Regarding current trading prices, TEVA is priced at $17.96, while DERM trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas DERM's P/E ratio is -9.49. In terms of profitability, TEVA's ROE is -0.26%, compared to DERM's ROE of -1.06%. Regarding short-term risk, TEVA is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs BIOA Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BIOA has a market cap of 145.91M. Regarding current trading prices, TEVA is priced at $17.96, while BIOA trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BIOA's P/E ratio is -0.61. In terms of profitability, TEVA's ROE is -0.26%, compared to BIOA's ROE of -1.12%. Regarding short-term risk, TEVA is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs THTX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, THTX has a market cap of 120.01M. Regarding current trading prices, TEVA is priced at $17.96, while THTX trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas THTX's P/E ratio is -37.29. In terms of profitability, TEVA's ROE is -0.26%, compared to THTX's ROE of +0.16%. Regarding short-term risk, TEVA is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs IRWD Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, IRWD has a market cap of 118.74M. Regarding current trading prices, TEVA is priced at $17.96, while IRWD trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas IRWD's P/E ratio is -3.86. In terms of profitability, TEVA's ROE is -0.26%, compared to IRWD's ROE of -0.09%. Regarding short-term risk, TEVA is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SCTL Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SCTL has a market cap of 116.13M. Regarding current trading prices, TEVA is priced at $17.96, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TEVA's ROE is -0.26%, compared to SCTL's ROE of -0.15%. Regarding short-term risk, TEVA is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs PROC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PROC has a market cap of 113.95M. Regarding current trading prices, TEVA is priced at $17.96, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PROC's P/E ratio is 1.53. In terms of profitability, TEVA's ROE is -0.26%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TEVA is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs OPTN Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, OPTN has a market cap of 95.40M. Regarding current trading prices, TEVA is priced at $17.96, while OPTN trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas OPTN's P/E ratio is -4.44. In terms of profitability, TEVA's ROE is -0.26%, compared to OPTN's ROE of +0.39%. Regarding short-term risk, TEVA is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ZOM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ZOM has a market cap of 95.35M. Regarding current trading prices, TEVA is priced at $17.96, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TEVA's ROE is -0.26%, compared to ZOM's ROE of -0.28%. Regarding short-term risk, TEVA is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs CRDL Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CRDL has a market cap of 93.37M. Regarding current trading prices, TEVA is priced at $17.96, while CRDL trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CRDL's P/E ratio is -3.05. In terms of profitability, TEVA's ROE is -0.26%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, TEVA is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs GRVI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, GRVI has a market cap of 88.91M. Regarding current trading prices, TEVA is priced at $17.96, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TEVA's ROE is -0.26%, compared to GRVI's ROE of -2.44%. Regarding short-term risk, TEVA is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs CPIX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CPIX has a market cap of 73.61M. Regarding current trading prices, TEVA is priced at $17.96, while CPIX trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CPIX's P/E ratio is -11.46. In terms of profitability, TEVA's ROE is -0.26%, compared to CPIX's ROE of -0.26%. Regarding short-term risk, TEVA is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs INCR Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, INCR has a market cap of 71.74M. Regarding current trading prices, TEVA is priced at $17.96, while INCR trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas INCR's P/E ratio is -3.71. In terms of profitability, TEVA's ROE is -0.26%, compared to INCR's ROE of -0.07%. Regarding short-term risk, TEVA is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ZYNE Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ZYNE has a market cap of 70.12M. Regarding current trading prices, TEVA is priced at $17.96, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TEVA's ROE is -0.26%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TEVA is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SSIC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SSIC has a market cap of 66.72M. Regarding current trading prices, TEVA is priced at $17.96, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TEVA's ROE is -0.26%, compared to SSIC's ROE of +0.06%. Regarding short-term risk, TEVA is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs VLNS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, VLNS has a market cap of 61.46M. Regarding current trading prices, TEVA is priced at $17.96, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TEVA's ROE is -0.26%, compared to VLNS's ROE of N/A. Regarding short-term risk, TEVA is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs ASRT Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ASRT has a market cap of 58.94M. Regarding current trading prices, TEVA is priced at $17.96, while ASRT trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ASRT's P/E ratio is -2.68. In terms of profitability, TEVA's ROE is -0.26%, compared to ASRT's ROE of -0.17%. Regarding short-term risk, TEVA is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs JUPW Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, JUPW has a market cap of 49.33M. Regarding current trading prices, TEVA is priced at $17.96, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TEVA's ROE is -0.26%, compared to JUPW's ROE of -0.06%. Regarding short-term risk, TEVA is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs QLI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, QLI has a market cap of 38.68M. Regarding current trading prices, TEVA is priced at $17.96, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas QLI's P/E ratio is -4.92. In terms of profitability, TEVA's ROE is -0.26%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TEVA is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs SCYX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SCYX has a market cap of 37.78M. Regarding current trading prices, TEVA is priced at $17.96, while SCYX trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SCYX's P/E ratio is -2.20. In terms of profitability, TEVA's ROE is -0.26%, compared to SCYX's ROE of -0.34%. Regarding short-term risk, TEVA is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs RMTI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, RMTI has a market cap of 35.54M. Regarding current trading prices, TEVA is priced at $17.96, while RMTI trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas RMTI's P/E ratio is -34.67. In terms of profitability, TEVA's ROE is -0.26%, compared to RMTI's ROE of -0.02%. Regarding short-term risk, TEVA is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs HEXO Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, HEXO has a market cap of 31.24M. Regarding current trading prices, TEVA is priced at $17.96, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TEVA's ROE is -0.26%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TEVA is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SXTC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SXTC has a market cap of 28.90M. Regarding current trading prices, TEVA is priced at $17.96, while SXTC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SXTC's P/E ratio is 0.02. In terms of profitability, TEVA's ROE is -0.26%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, TEVA is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs CYTH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CYTH has a market cap of 23.59M. Regarding current trading prices, TEVA is priced at $17.96, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TEVA's ROE is -0.26%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, TEVA is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs KALA Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, KALA has a market cap of 22.71M. Regarding current trading prices, TEVA is priced at $17.96, while KALA trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas KALA's P/E ratio is -0.35. In terms of profitability, TEVA's ROE is -0.26%, compared to KALA's ROE of -3.89%. Regarding short-term risk, TEVA is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs EGRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, EGRX has a market cap of 22.68M. Regarding current trading prices, TEVA is priced at $17.96, while EGRX trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas EGRX's P/E ratio is 2.06. In terms of profitability, TEVA's ROE is -0.26%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, TEVA is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs QNTM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, QNTM has a market cap of 20.97M. Regarding current trading prices, TEVA is priced at $17.96, while QNTM trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas QNTM's P/E ratio is -0.70. In terms of profitability, TEVA's ROE is -0.26%, compared to QNTM's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs DRRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, DRRX has a market cap of 20.80M. Regarding current trading prices, TEVA is priced at $17.96, while DRRX trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas DRRX's P/E ratio is -1.12. In terms of profitability, TEVA's ROE is -0.26%, compared to DRRX's ROE of -1.41%. Regarding short-term risk, TEVA is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs TXMD Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TXMD has a market cap of 17.13M. Regarding current trading prices, TEVA is priced at $17.96, while TXMD trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TXMD's P/E ratio is -7.40. In terms of profitability, TEVA's ROE is -0.26%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, TEVA is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs FLGC Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, FLGC has a market cap of 16.93M. Regarding current trading prices, TEVA is priced at $17.96, while FLGC trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas FLGC's P/E ratio is -0.58. In terms of profitability, TEVA's ROE is -0.26%, compared to FLGC's ROE of -3.31%. Regarding short-term risk, TEVA is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs ACRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ACRX has a market cap of 14.58M. Regarding current trading prices, TEVA is priced at $17.96, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TEVA's ROE is -0.26%, compared to ACRX's ROE of -0.40%. Regarding short-term risk, TEVA is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs SISI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, SISI has a market cap of 14.41M. Regarding current trading prices, TEVA is priced at $17.96, while SISI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas SISI's P/E ratio is -0.01. In terms of profitability, TEVA's ROE is -0.26%, compared to SISI's ROE of -0.84%. Regarding short-term risk, TEVA is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs GELS Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, GELS has a market cap of 13.59M. Regarding current trading prices, TEVA is priced at $17.96, while GELS trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas GELS's P/E ratio is -6.00. In terms of profitability, TEVA's ROE is -0.26%, compared to GELS's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs PRPH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, PRPH has a market cap of 13.53M. Regarding current trading prices, TEVA is priced at $17.96, while PRPH trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas PRPH's P/E ratio is -0.13. In terms of profitability, TEVA's ROE is -0.26%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, TEVA is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs COSM Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, COSM has a market cap of 11.72M. Regarding current trading prices, TEVA is priced at $17.96, while COSM trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas COSM's P/E ratio is -0.37. In terms of profitability, TEVA's ROE is -0.26%, compared to COSM's ROE of -0.51%. Regarding short-term risk, TEVA is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs TLPH Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, TLPH has a market cap of 10.69M. Regarding current trading prices, TEVA is priced at $17.96, while TLPH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas TLPH's P/E ratio is -1.04. In terms of profitability, TEVA's ROE is -0.26%, compared to TLPH's ROE of -1.11%. Regarding short-term risk, TEVA is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs AGRX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AGRX has a market cap of 10.43M. Regarding current trading prices, TEVA is priced at $17.96, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TEVA's ROE is -0.26%, compared to AGRX's ROE of +1.04%. Regarding short-term risk, TEVA is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs BFRIW Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BFRIW has a market cap of 8.51M. Regarding current trading prices, TEVA is priced at $17.96, while BFRIW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BFRIW's P/E ratio is -0.05. In terms of profitability, TEVA's ROE is -0.26%, compared to BFRIW's ROE of -4.60%. Regarding short-term risk, TEVA is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs NLTX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, NLTX has a market cap of 8.20M. Regarding current trading prices, TEVA is priced at $17.96, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TEVA's ROE is -0.26%, compared to NLTX's ROE of -0.09%. Regarding short-term risk, TEVA is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs AYTU Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, AYTU has a market cap of 7.65M. Regarding current trading prices, TEVA is priced at $17.96, while AYTU trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas AYTU's P/E ratio is -0.60. In terms of profitability, TEVA's ROE is -0.26%, compared to AYTU's ROE of -0.18%. Regarding short-term risk, TEVA is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs LCI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, LCI has a market cap of 7.38M. Regarding current trading prices, TEVA is priced at $17.96, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas LCI's P/E ratio is -0.04. In terms of profitability, TEVA's ROE is -0.26%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TEVA is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs CPHI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, CPHI has a market cap of 7.34M. Regarding current trading prices, TEVA is priced at $17.96, while CPHI trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas CPHI's P/E ratio is -0.83. In terms of profitability, TEVA's ROE is -0.26%, compared to CPHI's ROE of -0.63%. Regarding short-term risk, TEVA is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.
TEVA vs BGXX Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BGXX has a market cap of 7.26M. Regarding current trading prices, TEVA is priced at $17.96, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BGXX's P/E ratio is -0.76. In terms of profitability, TEVA's ROE is -0.26%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, TEVA is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs ADMP Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, ADMP has a market cap of 7.25M. Regarding current trading prices, TEVA is priced at $17.96, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TEVA's ROE is -0.26%, compared to ADMP's ROE of +0.00%. Regarding short-term risk, TEVA is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.
TEVA vs BFRI Comparison
TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 20.58B. In comparison, BFRI has a market cap of 6.45M. Regarding current trading prices, TEVA is priced at $17.96, while BFRI trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of -15.62, whereas BFRI's P/E ratio is -0.21. In terms of profitability, TEVA's ROE is -0.26%, compared to BFRI's ROE of -4.60%. Regarding short-term risk, TEVA is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for TEVA.